ORBITA-CTO
Percutaneous Coronary Intervention for Chronic Total Occlusion: A Randomized Placebo-Controlled Trial
Presented by Sarosh Khan — Imperial College London
Subspecialty: Interventional
Published in JACC
Key Result
CTO PCI significantly reduced angina symptoms vs sham procedure in the first placebo-controlled CTO trial: 31 more angina-free days over 168 days, with improved quality of life scores. No deaths, MIs, or withdrawals.
What did this trial find?
ORBITA-CTO was the first randomized, blinded, placebo-controlled trial of PCI for chronic total coronary occlusions, randomizing 50 patients to CTO PCI or sham procedure. CTO PCI resulted in 31 more angina-free days over 168 days, with significant improvements in angina symptom scores and quality of life, and no deaths, MIs, or withdrawals. Expert reaction was generally supportive but tempered by concerns about small sample size and the highly selected patient and operator population, with an accompanying editorial calling the evidence "invaluable" for a field that has relied on technical accomplishment as a surrogate for clinical effect.
Why does this trial matter?
Moderate controversy. The trial results are clearly positive but the debate centers on generalizability given the small sample size (n=50), highly selected patients (single-vessel CTO only), and very experienced operators. The editorial and outside commentators acknowledge the design's rigor while flagging that CTO PCI should remain limited to specialized centers. There is no fundamental disagreement about the direction of results, but meaningful interpretation debate about how broadly these findings apply.
Study Design
Multicenter, randomized, blinded, placebo-controlled trial (N=50)
Clinical Implications
First placebo-controlled evidence that CTO PCI provides genuine symptomatic benefit beyond placebo effect, supporting symptom-driven PCI in carefully selected patients through heart team selection at specialist CTO centers.
Abstract
ORBITA-CTO was the first randomized, blinded, placebo-controlled trial of PCI for chronic total coronary occlusions (CTOs). The trial randomized 50 patients with symptomatic single-vessel CTOs to either CTO PCI or sham procedure, with blinding maintained via auditory isolation and deep conscious sedation. Antianginal medications were stopped at randomization. CTO PCI patients experienced 31 more angina-free days on average during the 168-day follow-up period, with significant improvement in angina symptom scores and quality of life. No patients died, suffered heart attacks, or withdrew due to worsening angina.